A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

This is a first-in-human study testing the safety and dosing of a new drug called AST-201 in patients with advanced solid tumors that test positive for a protein called GPC3 — which is found in certain cancers, including liver cancer. **You may be eligible if...** - You are 19 years or older - You have been diagnosed with an advanced solid tumor that has not responded to standard treatments - Your tumor tests positive for GPC3 (a protein marker) on biopsy - You have at least one measurable or evaluable tumor site - You are physically functional (ECOG 0–1) and expected to live at least 12 weeks - Your heart, kidney, liver, and blood function are within acceptable ranges - If you have liver cancer (HCC), you have Child-Pugh Class A liver function **You may NOT be eligible if...** - You have ischemic heart disease - You received anti-cancer treatment in the past 4 weeks - You have uncontrolled high blood pressure or heart failure - You are pregnant, potentially pregnant, or breastfeeding Talk to your doctor to see if this trial is right for you.